You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

BRAF-Mutated Melanoma with immunotherapy progression

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Triple BRAFinh/MEKinh /antiPD1 Combined Therapy in BRAF Mutated

Recruiting
  • Metastatic Melanoma
    • Montpellier, France
      Uhmontpellier
    Aug 19, 2022

    Immunotherapy Among BRAF-Positive Melanoma Patients Treated in

    Completed
    • Metastatic Melanoma
    • East Hanover, New Jersey
      Novartis Investigative Site
    Nov 11, 2022

    Associated Factors, and Clinical Outcomes of Prescribing

    Completed
    • BRAF v600 Mutated Metastatic Melanoma
      • East Hanover, New Jersey
        Novartis Pharmaceuticals
      Mar 28, 2023

      Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Tumor in the Brain, Metastatic Malignant Tumor in the CNS

      Recruiting
      • Clinical Stage IV Cutaneous Melanoma AJCC v8
      • +3 more
      • Scottsdale, Arizona
      • +2 more
      Jan 4, 2023

      Melanoma Trial in Boston, Harrison, New York (Dabrafenib, Trametinib, Phenformin)

      Active, not recruiting
      • Melanoma
      • Boston, Massachusetts
      • +2 more
      Jun 14, 2022

      Melanoma Trial in Boston (MCS110, Dabrafenib, Trametinib)

      Active, not recruiting
      • Melanoma
      • Boston, Massachusetts
        Dana Farber Cancer Institute
      Dec 14, 2022

      Malignant Melanoma, Brain Metastases Trial in Tucson (E6201, E6201 plus dabrafenib)

      Terminated
      Has Results
      • Malignant Melanoma
      • Brain Metastases
      • Tucson, Arizona
        University of Arizona Cancer Center
      Mar 5, 2022

      Melanoma (Skin) Trial in Dijon, Thionville, Vandœuvre-lès-Nancy (Blood sampling)

      Active, not recruiting
      • Melanoma (Skin)
      • Blood sampling
      • Dijon, France
      • +3 more
      Mar 29, 2022

      Melanoma Trial in Tampa (XL888, Vemurafenib)

      Active, not recruiting
      • Melanoma
      • Tampa, Florida
        H. Lee Moffitt Cancer Center and Research Institute
      Aug 18, 2022

      Tumor Skin, Metastatic Melanoma, Melanoma Trial in Orlando, Louisville (OBX-115)

      Active, not recruiting
      • Tumor Skin
      • +2 more
      • OBX-115
      • Orlando, Florida
      • +1 more
      Sep 28, 2023

      Malignant Melanoma, Metastatic Melanoma, Immunotherapy Trial (Pembrolizumab, Encorafenib, Binimetinib)

      Not yet recruiting
      • Malignant Melanoma
      • +4 more
      • (no location specified)
      Mar 31, 2022

      Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma Trial in United States (Dabrafenib Mesylate, Tazemetostat

      Recruiting
      • Clinical Stage IV Cutaneous Melanoma AJCC v8
      • Metastatic Melanoma
      • Dabrafenib Mesylate
      • +2 more
      • Atlanta, Georgia
      • +6 more
      Nov 30, 2022

      Metastatic Melanoma, BRAF Gene Mutation Trial in Lexington (Nilotinib 100mg, Nilotinib 200mg, Nilotinib 300mg)

      Recruiting
      • Metastatic Melanoma
      • BRAF Gene Mutation
      • Nilotinib 100mg
      • +5 more
      • Lexington, Kentucky
        Markey Cancer Center
      Jul 22, 2022

      Metastatic Malignant Tumor in the Brain, Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7 Trial in Houston (drug,

      Active, not recruiting
      • Metastatic Malignant Neoplasm in the Brain
      • +7 more
      • Houston, Texas
        M D Anderson Cancer Center
      Jun 15, 2022

      BRAF V600E Unresectable or Metastatic Melanoma, BRAF V600E Metastatic NSCLC, Melanoma Trial in Guangzhou (Encorafenib)

      Completed
      • BRAF V600E Unresectable or Metastatic Melanoma
      • +2 more
      • Guangzhou, Guangdong, China
        Sun Yat-sen University Cancer Center
      Jun 9, 2022

      Targeted Therapies in BRAF Positive Metastatic Melanoma in US

      Active, not recruiting
      • Melanoma
      • New York, New York
        Pfizer Investigational Site
      Feb 18, 2022

      Melanoma Trial in Italy (Cobimetinib 20 MG Oral Tablet, Vemurafenib 240 Mg Oral Capsule, Atezolizumab 1200 MG in 20 ML

      Recruiting
      • Melanoma
      • Cobimetinib 20 MG Oral Tablet
      • +2 more
      • Bagno A Ripoli, Firenze, Italy
      • +5 more
      Apr 12, 2022

      Patterns for Immunotherapy Agents and BRAF/MEK Inhibitors Used

      Completed
      • Melanoma
      • Non-Interventional
      • Boston, Massachusetts
        Local Institution
      Jan 27, 2022

      Melanoma Trial in Pierre-Bénite (Skin biopsy)

      Recruiting
      • Melanoma
      • Skin biopsy
      • Pierre-Bénite, France
        Service de Dermatologie, Centre hospitalier Lyon Sud, HCL
      Jul 5, 2021

      Advanced Solid Tumors, EGFR Positive NSCLC, Colorectal Carcinoma Trial in United States (TP-0903)

      Active, not recruiting
      • Advanced Solid Tumors
      • +4 more
      • Phoenix, Arizona
      • +15 more
      Apr 4, 2022

      Pyrexia Trial in Zürich (Actemra)

      Recruiting
      • Pyrexia
      • Zürich, Switzerland
        University Hospital Zurich, Clinic of Dermatology
      Sep 29, 2021

      Melanoma, BRAF Gene Mutation Trial in Germantown (Talimogene Laherparepvec 1 Million Pfu/Ml Inj,Susp,1Ml,Vil, Talimogene

      Unknown status
      • Melanoma
      • BRAF Gene Mutation
      • Talimogene Laherparepvec 1 Million Pfu/Ml Inj,Susp,1Ml,Vil
      • +3 more
      • Germantown, Tennessee
        West Cancer Center
      Oct 9, 2020

      Metastatic Melanoma Trial in Worldwide (LGX818, MEK162, Nivolumab)

      Active, not recruiting
      • Metastatic Melanoma
      • Salzburg, AT, Austria
      • +29 more
      Feb 23, 2022

      Metastatic Melanoma Trial in Netherlands (drug, device, procedure)

      Terminated
      • Metastatic Melanoma
      • Vemurafenib plus cobimetinib
      • +3 more
      • Amsterdam, Netherlands
      • +9 more
      Nov 24, 2022

      Melanoma Metastatic, BRAF V600 Mutation Trial in Italy (Experimental combination beyond Focal Progression, Pembrolizumab or

      Active, not recruiting
      • Melanoma Metastatic
      • BRAF V600 Mutation
      • Experimental combination beyond Focal Progression
      • Pembrolizumab or Nivolumab
      • Bari, BA, Italy
      • +13 more
      Dec 1, 2021